Efficacy of the treatment
in vivo. Experimental metastases were induced by intravenous injection of MDA-MB-231/EGFP cells. The presence of human cells in lungs was evaluated by flow cytometry (B-E) and by qPCR (F). A: Time line of in vivo treatment. B: Ability of intravenously administered fluorescently labeled AT-MSC to home into mouse lungs. C: Presence of the EFGP-positive tumor cells in lung tissue in untreated mouse which received only MDA-MB-231/EGFP cells (an example is presented, we detected 0.28 – 41.6% of viable EGFP-positive cells in mouse lungs, median 4.45). D: Absence of EGFP-expressing cells in mouse which received combined GDEPT mediated by engineered AT-MSC. E: Summary table of flow cytometric evaluation of the efficacy of individual treatment approaches. F: Molecular analysis of lungs. Human β-globin was detected and the amount was calculated according to 150 ng of total DNA. Highly significant difference (p < 0.0001) in amount of human DNA between untreated and double treated animals was detected.